Mesoblast (MESO) Free Cash Flow Growth (5y) (2021 - 2023)

Mesoblast (MESO) Free Cash Flow Growth (5y) (2021 - 2023) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn
7 Belite Bio 61.40 Bn 61.40 Bn -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn
9 Revolution Medicines 37.37 Bn 37.37 Bn -
10 Mesoblast 19.81 Bn 19.68 Bn -

Historic Data

Download Data
DateValue
Jun 30, 2023 4.21%
Mar 31, 2023 3.68%
Dec 31, 2022 -2.05%
Sep 30, 2022 6.84%
Jun 30, 2022 9.93%
Mar 31, 2022 9.63%
Dec 31, 2021 6.53%
Sep 30, 2021 2.66%
Mar 31, 2021 -2.12%